Abstract. Corticotropin releasing hormone binding protein (CRHBP) mediates the reaction between corticotropin releasing hormone (CRH) and corticotropin releasing hormone receptors (CRHRs). It is expressed in a number of organs, and the expression of CRHBP is associated with tumorigenesis and cancer progression. The aim of the present study was to investigate CRHBP expression levels in hepatocellular carcinoma (HCC) and its association with patient clinicopathological characteristics as well as prognosis. The expression of CRHBP was examined by immunohistochemistry in 169 HCC tissues and 151 adjacent non-tumorous tissues. The results were validated by western blotting using patient tissues and liver cancer cell lines. The association of CRHBP expression with clinicopathological patient characteristics and survival rate was analyzed statistically. Expression of CRHBP was detected in 142/151 (94.0%) non-tumorous liver tissues, and 84/169 (49.7%) HCC tissues (P<0.001). The expression of CRHBP was negatively associated with tumor size (P=0.013), Edmondson Grade (P=0.002), hepatitis B virus antigen (P=0.020), and α-fetoprotein levels (P=0.014). Patients exhibiting low CRHBP expression were associated with shorter survival time compared with those exhibiting high CRHBP expression (P=0.012). The results of western blotting analysis suggest that reduced CRHBP expression is frequently observable in patients with HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common types of malignancies, and ranks as the fifth most prevalent cancer worldwide (1, 2) . Tumorigenesis is a complicated process, physical, chemical, and biological factors could lead to mutations in genes and the formation of tumors (3) . HCC is common in China with an incidence rate of 250.28/100,000 and accounts for >50% of cancer cases worldwide (4, 5) , which causes a heavy economic and physical burden to patients. Despite progress in conventional therapies, including surgical resection, percutaneous ablation, chemotherapy and embolization treatment, the 5-year survival rate of patients with HCC remains poor (6) . Tumors have the characteristic of metastasis, which impedes of the ability of complete surgical resection, and recurrence is the biggest obstacle for the treatment of tumors (7) . This suggests that diagnosis of HCC at an early stage is crucial for effective therapy and good prognosis, and highlights the urgent requirement for identification of biomarkers of HCC.
Corticotropin releasing hormone binding protein (CRHBP) is a 37-kDa oligopeptide, and is a component of the hypothalamic-pituitary-adrenal axis, involved in regulation of physiological reactions (8) . Expression of CRHBP has been detected in numerous tissue types (9, 10) . CRHBP prevents inappropriate activation of corticotropin releasing hormone (CRH) by binding the CRH complex (11) .
CRHBP has been investigated in the field of normal physiologic, metabolic function and oncogenesis (12, 13) . It was reported that Caucasians and African Americans with low CRHBP expression were associated with an increased risk of breast cancer (14) . Low CRHBP mRNA and protein expression has been reported in prostatic and bladder cell carcinoma (15, 16) .
Because the study of CRHBP expression in HCC tissue is unclear, the present study used immunohistochemistry, western blotting and reverse transcription-quantitative Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma HAI-BING XIA  1-3* , HUI-JU WANG   2,3*   , LUO-QIN FU  2,3 , SHI-BING WANG  2,3 , LI LI  2,3 , GUO-QING RU  2-4 ,   XIANG-LEI HE  2-4 , XIANG-MIN TONG  2,3 , XIAO-ZHOU MOU  2,3 and DONG-SHENG HUANG polymerase chain reaction (RT-qPCR) and bioinformatics analysis to evaluate the expression level of CRHBP in HCC.
The association between CRHBP expression and clinicopathology and overall survival time was also investigated. RT-qPCR analysis. Total RNA was isolated from five liver cancer cell lines (HCCLM3, MHCC97H, Huh7, Hep3B, HepG2) using TRIzol Reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. cDNAs were synthesized from 1 µg of DNase-treated total RNA using the PrimeScriptTM RT reagent kit with gDNA Eraser (Takara Bio, Inc., Otsu, Japan), under 65˚C, 5 min, 42˚C, 60 min and 70˚C, 10 min of reverse transcription. The primers of CRHBP were 5'-CAC ACC AGC ATC GAA ACT GC-3' (forward) and 5'-TGA AGA CCA TTT ACG TGT CCC A-3' (reverse). The Primers for GAPDH were 5'-TGA AGG TCG GAG TCA ACG G-3' (forward) and 5'-CTG GAA GAT GGT GAT GGG ATT-3' (reverse). qPCR was carried out using a Bio-Rad CFX Connect Real-Time system (Bio-Rad Laboratories, Inc) using the thermal cycling condition: 98˚C for 2 min followed by 39 amplification cycles at 98˚C for 15 sec and 60˚C for 15 sec. At the end of the PCR cycles, melting curve analysis were performed. The expression of CRHBP was normalized to GAPDH using 2 -ΔΔCq method (17) .
Materials and methods

Patients
Bioinformatics analysis using online databases and search tool for the retrieval of interacting genes/proteins. CRHBP mRNA expression in HCC and normal tissues was compared using the online Oncomine database (https://www.oncomine.org) with the following filtering conditions: Gene, CRHBP; analysis type, cancer vs. normal; cancer type, hepatocellular carcinoma; data type, mRNA. The 10-year survival analysis was performed using OncoLnc (http://www.oncolnc.org/). Gene enrichment analysis of CRH was performed using STRING (https://string-db.org/) as there was not enough CRHBP data in the online database, and the top 20 enriched genes analyzed to investigate its biological function. Target signaling pathway was searched on KEGG database (www.genome.jp).
Statistical analysis. Statistical analysis was performed using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). χ 2 test was used to analyze the association between CRHBP expression and clinicopathological parameters. The overall survival curve was generated using the Kaplan-Meier method and further analyzed using the log-rank test. P<0.05 was considered to indicate a statistically significant difference.
Results
Clinical characteristics of patients. The majority of the patients who participated in the present study had a history of hepatitis B virus infection (79.3%). Upon the last day of follow-up, 84 patients were alive and 41 mortalities had occurred. A total of 44 patients were lost to follow-up (Table I) .
CRHBP expression in HCC. Positive immunohistochemical staining of CRHBP was detected in 84/169 (49.7%) HCC tissues and 142/151 (94.0%) adjacent non-tumorous tissues. The expression of CRHBP in tumor tissues was significantly lower than that in adjacent non-tumorous tissues (P<0.001; Table II ; Fig. 1A and B) . A bar chart illustrating the score values of the immunostaining of CRHBP expression in HCC tissues (Fig. 1C) .
The association bet ween CR HBP expression and clinicopathological characteristics. Tumor diameters ≥5 cm were significantly associated with low expression of CRHBP Table I . Associations between expression of CRHBP protein and clinicopathological characteristics in 169 cases of hepatocellular carcinoma. (P= 0.013). Low CRHPB expression was also significantly associated with Edmondson Grade (P=0.002), high α-fetoprotein (AFP) levels (P=0.014) and hepatitis B virus (HBV) infection (P= 0.020). No significant association was identified between CRHBP expression and age, sex, tumor location, metastasis status, microvascular invasion or cirrhosis (P>0.05; Table I ).
CRHBP expression -------------------------------------
CRHBP expression ---------------------------------------
Association between CRHBP expression and prognosis.
To evaluate the prognostic value of CRHBP expression, Kaplan-Meier curves were constructed. The 5-year overall survival rate was significantly different between patients exhibiting low CRHBP expression (39.20 months) and patients exhibiting high CRHBP expression (49.18 months) (P=0.012; log-rank test; Fig. 2 ). Thus, it was inferred that patients exhibiting low CRHBP expression in the liver tissue had a reduced survival time compared with those exhibiting high CRHBP expression.
CRHBP is downregulated in liver cancer tissues and cell lines.
To further confirm the expression pattern of CRHBP in HCC, the protein expression level of CRHBP was determined in paired HCC and adjacent non-cancerous liver tissues by western blotting. Compared with the adjacent non-tumor tissues, significant downregulation of CRHBP protein expression was observed in HCC tissues ( Fig. 3A and B) . Furthermore, CRHBP levels were lower in highly metastatic liver cancer cell lines, including HCCLM3 and MHCC97H cells, than in those with low metastatic potential, including Huh7 and Hep3B cells, and was highest in HepG2 hepatic cancer cells as determined by western blotting and RT-qPCR ( Fig. 3C and D) . These results suggest that reduced CRHBP expression is common in patients with HCC, and that this may be associated with tumorigenesis.
Bioinformatics analysis of CRHBP in patients with HCC.
A total of 5 datasets: Wurmbach Liver Statistics (18), Chen Liver Statistics (19), Roessler Liver Statistics, Roessler Liver 2 Statistics (20) and Mas Liver Statistics (21) , were selected to analyze the expression of CRHBP in HCC vs. normal tissues using Oncomine databases. It was demonstrated that the expression of CRHBP mRNA was significantly lower in HCC tissues than in normal tissues ( Fig. 4; P<0.01) . OncoLnc was used to reveal that patients exhibiting low expression of CRHBP had a shorter 10-year survival time ( Fig. 5 ; log-rank, P=0.0122). STRING was used to identify the top 20 biological processes of CRH gene enrichment (Table III) and a part of an important signaling pathway of cAMP was generated on KEGG database (Fig. 6) .
Discussion
Oncogenesis is a multi-factorial process, and numerous genes have been identified to be involved in HCC oncogenesis (22) . However, the role of CRHBP expression in HCC remains unclear. The aim of the present study was to investigate the association between CRHBP expression and HCC.
Low expression of CRHBP was associated with large tumor size (P=0.013) and high Edmondson Grade (P=0.002). This supports previous research in human kidney cancer which suggested that low expression of CRHBP in kidney tumor cell lines could promote proliferation (16) . In the present study, microvascular invasion and metastasis had no association with CRHBP expression; however, Tezval et al (15) reported that clear cell renal cell cancer with low expression of CRHBP had strong invasion and metastasis. This may be due to the different sources of the tissues or the change from in vivo to ex vivo microenvironment. Besides, as CRHBP has a high affinity for CRH and urocortin (23), we could infer that when CRHBP expression was downregulated, the stimulate signal from CRH would be decreased, and the physiological of the hepatocyte might be changed. As it has been previously reported that CRH promotes the proliferation of human colon cancer cells and upregulates VEGF expression (24) . Gene enrichment analysis of the biological processes associated with CRH indicated that CRH may regulate cytobiological state via the cAMP signaling pathway. We hypothesize that CRHBP may prevent CRH from activating CRHRs in incorrect locations or in excess. Although HBV infection was demonstrated to be associated with CRHBP expression (P=0.020), the molecular mechanism behind downregulation of CRHBP following HBV infection remains uncharacterized. Previous research suggests that CRBHP expression was decreased following long-term stimulation by HBV (13, 25, 26) , and that The results of the present study may have valuable clinical application. Upregulation of CRHBP expression may inhibit the proliferation of hepatocellular carcinoma cells as well as tumor progression. Clinicians should be aware of the significance of HBV infection when considering therapeutic strategies.
In conclusion, CRHBP expression was demonstrated to be associated with high AFP level and overall survival rate in HCC, and may be a potential biomarker for HCC diagnosis, treatment and prognosis.
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